Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/DNTH · Entity 1813 | Director | May 23, 2024 | May 28, 2024 |
| TREVENA INCTRVN · Entity 85383 | Director | June 15, 2023 | June 20, 2023 |
| Zai Lab LtdZLAB · Entity 4271 | Director | June 17, 2026 | June 22, 2026 |
| Zenas BioPharma, Inc.ZBIO · Entity 275 | Director · See Remarks | June 15, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date May 23, 2024 · Filed May 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.77 · Expires 2034-05-22 | Direct | 11,000 |
Reported balance
After 2024-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-23 · Grant · Acquired 11,000 · Balance 11,000 F1: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.
TREVENA INC
Report date June 15, 2023 · Filed June 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2033-06-15 | Direct | 13,700 |
Reported balance
After 2023-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-15 · Grant · Acquired 13,700 · Balance 13,700 F1: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date.
Zai Lab Ltd
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 94,973 |
Reported balance
After 2026-06-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 22,371 · Balance 94,973 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date.
Zenas BioPharma, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.71 · Expires 2036-06-15 | Direct | 500,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 500,000 · Balance 500,000 F1: The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TESARO, Inc.
Report date January 22, 2019 · Filed January 22, 2019
Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 1
1 source rowRow 1 · 2019-01-22 · Other · Disposed 1,034,664 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). |
| Common StockSEC Table I · non-derivative | IndirectBy The Leon Moulder Revocable Trust | 0 |
Reported balance
After 2019-01-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-01-22 · Other · Disposed 5,000 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-22 · Disposition to issuer · Disposed 10,007 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-01-22 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2021-07-19 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-01-22 · Disposition to issuer · Disposed 314,285 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.62 · Expires 2022-03-16 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-01-22 · Disposition to issuer · Disposed 371,428 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.18 · Expires 2023-03-06 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-01-22 · Disposition to issuer · Disposed 200,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.74 · Expires 2024-02-27 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-01-22 · Disposition to issuer · Disposed 125,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.11 · Expires 2025-03-06 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-01-22 · Disposition to issuer · Disposed 140,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.39 · Expires 2026-03-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-01-22 · Disposition to issuer · Disposed 100,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $178.95 · Expires 2027-03-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-01-22 · Disposition to issuer · Disposed 24,260 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.84 · Expires 2028-03-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-01-22 · Disposition to issuer · Disposed 87,873 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.
F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]
F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:08 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 22,371 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003025 · form4.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,973 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 22:02 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $18.71 | $0.00 |
DisclosureSEC source: 0001104659-26-075256 · tm2618042-8_4seq1.xml · derivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2036-06-15 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service. Read SEC document |
| May 18, 2026 Filed May 19, 2026 01:12 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 60,000 | $16.88 | $1,012,800.00 |
DisclosureSEC source: 0001104659-26-063362 · tm2615027-1_4seq1.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 96,928 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $16.59 to $16.97, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: The reporting person is a Trustee of the Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008 (the "Trust") and may be deemed to have voting and dispositive power over the shares held by the Trust. The reporting person is the Issuer's chief executive officer and Chairman of its board of directors. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 29, 2026 Filed Apr 29, 2026 23:21 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 35,000 | $17.62 | $616,700.00 |
DisclosureSEC source: 0001104659-26-051889 · tm2613154-1_4seq1.xml · nonDerivative · entry 2 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,786,039 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.56 to $17.67, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 28, 2026 Filed Apr 29, 2026 23:21 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 25,000 | $18.02 | $450,500.00 |
DisclosureSEC source: 0001104659-26-051889 · tm2613154-1_4seq1.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,751,039 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.87 to $18.05, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 00:14 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 34,000 | $19.31 | $656,540.00 |
DisclosureSEC source: 0001104659-26-038031 · tm2610818-1_4seq1.xml · nonDerivative · entry 2 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,726,039 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $18.84 to $19.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 00:14 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 20,000 | $18.23 | $364,600.00 |
DisclosureSEC source: 0001104659-26-038031 · tm2610818-1_4seq1.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,692,039 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $18.195 to $18.25, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:30 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 57,000 | $17.96 | $1,023,720.00 |
DisclosureSEC source: 0001104659-26-009756 · tm264991-1_4seq1.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 423,155 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.69 to $18.14, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| January 09, 2026 Filed Jan 10, 2026 02:42 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 20,000 | $16.55 | $331,000.00 |
DisclosureSEC source: 0001104659-26-002589 · tm262858-1_4seq1.xml · nonDerivative · entry 3 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,155 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $16.05 to $16.87, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| January 08, 2026 Filed Jan 10, 2026 02:42 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 30,000 | $16.30 | $489,000.00 |
DisclosureSEC source: 0001104659-26-002589 · tm262858-1_4seq1.xml · nonDerivative · entry 2 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,155 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $15.82 to $16.60, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 02:42 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 50,000 | $16.38 | $819,000.00 |
DisclosureSEC source: 0001104659-26-002589 · tm262858-1_4seq1.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,155 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $16.21 to $16.53, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 21:24 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 36,928 | $20.85 | $769,948.80 |
DisclosureSEC source: 0001104659-25-098413 · tm2528454-2_4seq1.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 36,928 F1 · price: On October 7, 2025, the Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008 (the "Trust"), of which the reporting person is a Trustee, entered into a Securities Purchase Agreement, dated as of October 7, 2025, by and among the Issuer and the investors party thereto, pursuant to which the Trust acquired 36,928 shares of common stock at a purchase price of $20.85 per share. F2 · ownership.nature: The reporting person is a Trustee of the Trust and may be deemed to have voting and dispositive power over the shares held by the Trust. The reporting person is the Issuer's chief executive officer and Chairman of its board of directors. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:11 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 10,831 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002219 · form4.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,602 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 18, 2026, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:30 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001104659-25-058914 · tm2517684-1_4seq1.xml · derivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on June 10, 2026, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:01 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 25,000 | $6.67 | $166,750.00 |
DisclosureSEC source: 0001104659-25-015145 · tm257089-1_4seq1.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,155 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $6.54 to $6.91, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 02:03 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 45,000 | $9.98 | $449,100.00 |
DisclosureSEC source: 0001104659-24-125677 · tm2430232-1_4seq1.xml · nonDerivative · entry 2 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,155 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $9.81 to $10.26, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 02:03 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 25,000 | $10.76 | $269,000.00 |
DisclosureSEC source: 0001104659-24-125677 · tm2430232-1_4seq1.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,155 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $10.73 to $10.88, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 22:20 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 2,500 | $14.57 | $36,425.00 |
DisclosureSEC source: 0001104659-24-121081 · tm2429053-1_4seq1.xml · nonDerivative · entry 2 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,155 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $14.50 to $14.62, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 22:20 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 7,500 | $15.00 | $112,500.00 |
DisclosureSEC source: 0001104659-24-121081 · tm2429053-1_4seq1.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,655 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $14.81 to $15.32, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| September 20, 2024 Filed Sep 20, 2024 22:34 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 2,633 | $18.97 | $49,948.01 |
DisclosureSEC source: 0001104659-24-101773 · tm2424498-1_4seq1.xml · nonDerivative · entry 4 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,672,039 F5 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $18.35 to $19.24, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 20, 2024 Filed Sep 20, 2024 22:34 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 2,367 | $17.88 | $42,321.96 |
DisclosureSEC source: 0001104659-24-101773 · tm2424498-1_4seq1.xml · nonDerivative · entry 3 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,669,406 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.70 to $18.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 22:34 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 5,000 | $17.89 | $89,450.00 |
DisclosureSEC source: 0001104659-24-101773 · tm2424498-1_4seq1.xml · nonDerivative · entry 2 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,667,039 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.64 to $18.00, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 22:34 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 10,000 | $17.91 | $179,100.00 |
DisclosureSEC source: 0001104659-24-101773 · tm2424498-1_4seq1.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,662,039 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.50 to $18.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:46 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionSeries B Convertible Preferred Stock · Derivative | 418,996 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100325 · tm2424157-12_4seq1.xml · derivative · entry 8 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:46 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionSeries B Convertible Preferred Stock · Derivative | 3,230,268 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100325 · tm2424157-12_4seq1.xml · derivative · entry 7 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 372,017 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:46 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionSeries A Convertible Preferred Stock · Derivative | 941,088 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100325 · tm2424157-12_4seq1.xml · derivative · entry 6 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,381 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · derivative.exercise_date: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · derivative.expiration_date: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:46 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionSeries Seed Convertible Preferred Stock · Derivative | 1,428,571 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100325 · tm2424157-12_4seq1.xml · derivative · entry 5 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 164,523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:46 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionCommon Stock | 48,254 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100325 · tm2424157-12_4seq1.xml · nonDerivative · entry 4 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:46 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionCommon Stock | 372,017 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100325 · tm2424157-12_4seq1.xml · nonDerivative · entry 3 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 536,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:46 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionCommon Stock | 108,381 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100325 · tm2424157-12_4seq1.xml · nonDerivative · entry 2 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:46 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionCommon Stock | 164,523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100325 · tm2424157-12_4seq1.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 164,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:54 UTC Amendment | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionSeries B Convertible Preferred Stock · Derivative | 418,996 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100765 · tm2424157-14_4aseq1.xml · derivative · entry 8 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · derivative.exercise_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · derivative.expiration_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:54 UTC Amendment | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionSeries B Convertible Preferred Stock · Derivative | 3,230,268 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100765 · tm2424157-14_4aseq1.xml · derivative · entry 7 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 372,017 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · derivative.exercise_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · derivative.expiration_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:54 UTC Amendment | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionSeries A Convertible Preferred Stock · Derivative | 941,088 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100765 · tm2424157-14_4aseq1.xml · derivative · entry 6 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,381 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. F4 · price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:54 UTC Amendment | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionSeries Seed Convertible Preferred Stock · Derivative | 1,428,571 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100765 · tm2424157-14_4aseq1.xml · derivative · entry 5 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 164,523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:54 UTC Amendment | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionCommon Stock | 48,254 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100765 · tm2424157-14_4aseq1.xml · nonDerivative · entry 4 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · balance_after: This amendment is being filed solely to correct the previously reported "Amount of Securities Beneficially Owned Following Reported Transactions." This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:54 UTC Amendment | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionCommon Stock | 372,017 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100765 · tm2424157-14_4aseq1.xml · nonDerivative · entry 3 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,652,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · balance_after: This amendment is being filed solely to correct the previously reported "Amount of Securities Beneficially Owned Following Reported Transactions." This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported. F3 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:54 UTC Amendment | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionCommon Stock | 108,381 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100765 · tm2424157-14_4aseq1.xml · nonDerivative · entry 2 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · balance_after: This amendment is being filed solely to correct the previously reported "Amount of Securities Beneficially Owned Following Reported Transactions." This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:54 UTC Amendment | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionCommon Stock | 164,523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100765 · tm2424157-14_4aseq1.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,280,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · balance_after: This amendment is being filed solely to correct the previously reported "Amount of Securities Beneficially Owned Following Reported Transactions." This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported. F3 · ownership.nature: Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 12, 2024 Filed Sep 17, 2024 00:46 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 1,486,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-24-100325 · tm2424157-12_4seq1.xml · derivative · entry 9 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,486,000 Underlying: Common Stock · 1,486,000 shares Expires 2034-09-11 F5 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on September 12, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service. Read SEC document |
| September 12, 2024 Filed Sep 18, 2024 00:54 UTC Amendment | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 1,486,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-24-100765 · tm2424157-14_4aseq1.xml · derivative · entry 9 MOULDER LEON O JR · CIK 0001228865 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,486,000 Underlying: Common Stock · 1,486,000 shares Expires 2034-09-11 F6 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on September 12, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:00 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 21,253 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001750 · form4.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,771 F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 18, 2025, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 23:58 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0000950170-24-065543 · ownership.xml · derivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 00:04 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantCommon Stock | 166,667 | $12.00 | $2,000,004.00 |
DisclosureSEC source: 0000950170-24-007137 · ownership.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,436,745 F1 · shares: Consists of 166,667 shares of common stock purchased by Tellus BioVentures, LLC ("Tellus") from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · ownership.nature: The securities reported are held of record by Tellus. The Reporting Person may be deemed to have voting and dispositive control over the shares held by Tellus. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 11, 2023 Filed Sep 14, 2023 01:13 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $11.20 | $0.00 |
DisclosureSEC source: 0000899243-23-018862 · doc4.xml · derivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2033-09-10 F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,500 shares of the Issuer's common stock, which will vest in full on the date that is the earlier of (i) the Issuer's 2024 Annual Meeting of Stockholders and (ii) September 11, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:06 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 18,903 | $26.45 | $499,984.35 |
DisclosureSEC source: 0000950170-23-031100 · ownership.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,518 F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:36 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 13,700 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001062993-23-013828 · form4.xml · derivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,700 Underlying: Common Stock · 13,700 shares Expires 2033-06-15 F1 · derivative.exercise_date: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 21:27 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001062993-22-014809 · form4.xml · derivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:14 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantOrdinary Shares | 7,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000398 · doc1.xml · nonDerivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,615 Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 21:01 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 68,577 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001429560-21-000005 · edgar.xml · derivative · entry 1 MOULDER LEON O JR · CIK 0001228865 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,577 Underlying: Common Stock · 68,577 shares Expires 2031-05-28 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.